Harvard Business Review

MAY 2, 2011

Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies. Another CEO of a fast-growing biotechnology venture, a Chinese-American entrepreneur, added that he wanted his company to be perceived as American rather than as Chinese.

Globalization 14

Globalization Marketing Venture Capitalist Biotechnology 14

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. economy, expands America's global trade, and attracts foreign companies to base operations in the U.S.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

SEPTEMBER 14, 2011

In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. To best leverage worldwide creative talent, Reliance MediaWorks operates a global network of creative centers located in Burbank, San Francisco, London, Tokyo, and across India. and the U.K.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

JUNE 16, 2016

The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. “But here, we can operate within the time frame of the next coffee break.” In 2011, he commissioned a report that called for an “innovation policy” rather than an “industrial policy.” Dr. Mukesh V.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MARCH 5, 2012

And one look at the trade deficit ($558 billion in 2011) clearly indicates we don't have as much as our foreign competitors to sell in return. This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. To make up the difference, we just borrow.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Consider the 2×2 matrix below.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22